Table 1.
Summary of the included studies
| Author | Study design | Patient characteristics | Sample (n) | Antibiotic envelope (n) | Antibiotic envelope type | Age (years ± SD) | Male (%) | Major infection | Mortality | Follow‐up |
|---|---|---|---|---|---|---|---|---|---|---|
| Tarakji (WRAP‐IT) 2019 | Randomized controlled trial | Patient at increased risk for CIED infection | 6983 | 3495/3488 | TYRX | 70.05 ± 12.5 | 71.7 | 25(0.72)/ 42(1.2) | 349(10)/ 365(10.5) | 20.7 ± 8.5 months |
| Henrikson (Citadel/Centurion) [Medicare Control] 2017 | Multicenter prospective cohort | >18 years of age undergoing CIED replacement with an ICD (Citadel) or CRT (Centurion) | 22 012 | 578/21434 | TYRX | N/A | N/A | 4 (0.7)/ 285(1.3) | 64(11)/2873(13.4 | 12 months |
| Hassoun 2017 | Retrospective cohort | Patient undergoing CIED implantation | 184 | 92/92 | AIGISRx (TYRX) | 69/73 | 60 | 5(5.4)/ 1(1.08) | 2(2.2)/0(0) | 9 months |
| Kolek 2015 | Retrospective cohort | ≥2 risk factors for CIED infection | 1124 | 488/636 | TYRX (353)/ TYRX‐A(135) | Median 67‐70 | 65.3 | 1(0.2)/ 20(3.1) | N/A | 569 days (524‐640) & 559 days (435‐768) |
| Shariff 2015 | Retrospective cohort | Every patient undergoing a CIED procedure in the electrophysiology laboratory | 1476 | 365/1111 | AIGISRx (TYRX) | 70 ± 15.2 | 64.8 | 0(0)/ 19(1.7) | 15(4.1)/74(6.7) | 6 months |
| Mittal 2014 | Retrospective cohort | Patient at high risk for CIED infection | 550 | 275/275 | AIGISRx (TYRX) | 74.5 ± 11.5 | 74.2 | 3(1.1)/ 10(3.6) | N/A | 6 months |
Abbreviations: CIED = Cardiac Implantable Electronic Devices; CRT = Cardiac Resynchronization Therapy; ICD = Implantable Cardioverter Defibrillator; N/A = Not Applicable/Available; WRAP‐IT = Worldwide Randomized Antibiotic Envelope Infection Prevention Trial